Skip to main content
Only direct cytotoxic targets are shown
Gene
Drug Category
Drug Class
Download CSV
Gene NCT ID Antigen/Ligand Binding Type Drug Name Drug NCI Concept Drug Category Drug Class Drug Description Drug Mechanism of Action Target Cytotoxicity Mechanism Disease Disease Type Tissue OncoTree Main Type OncoTree Name Annotation Status
BTN3A1 NCT05755854 BTN3A1 antigen recognition Allogeneic Vγ9Vδ2 T cells CULTURED CELLS Unedited cells Adoptive cellular immunotherapy using ex vivo expanded allogeneic gamma-delta (Vγ9Vδ2) T lymphocytes that recognize phosphoantigens via BTN3A1/BTN2A1 and stress ligands via NKG2D to mediate HLA-independent cytotoxicity. Ex vivo expanded allogeneic Vγ9Vδ2 T cells that recognize tumor-associated phosphoantigens via BTN3A1/BTN2A1 and stress-induced ligands via NKG2D, enabling HLA-independent cytotoxicity through perforin/granzyme release and cytokine production. Allogeneic Vγ9Vδ2 T cells recognize phosphoantigen-induced BTN3A1/BTN2A1 complexes on target cells via their TCR and directly lyse them through perforin/granzyme release (with supportive cytokine-mediated cytotoxicity). Hematologic Diseases CANCER Other Lymphatic Cancer Lymphoid Neoplasm ai
BTN2A1 NCT05755854 BTN2A1 antigen recognition Allogeneic Vγ9Vδ2 T cells CULTURED CELLS Unedited cells Adoptive cellular immunotherapy using ex vivo expanded allogeneic gamma-delta (Vγ9Vδ2) T lymphocytes that recognize phosphoantigens via BTN3A1/BTN2A1 and stress ligands via NKG2D to mediate HLA-independent cytotoxicity. Ex vivo expanded allogeneic Vγ9Vδ2 T cells that recognize tumor-associated phosphoantigens via BTN3A1/BTN2A1 and stress-induced ligands via NKG2D, enabling HLA-independent cytotoxicity through perforin/granzyme release and cytokine production. Vγ9Vδ2 T cells engage the BTN3A1/BTN2A1 complex induced by phosphoantigens on target cells, activating HLA‑independent cytotoxicity and killing via perforin/granzyme (and death‑receptor) pathways. Hematologic Diseases CANCER Other Lymphatic Cancer Lymphoid Neoplasm ai
MICA NCT05755854 MICA receptor ligand recognition Allogeneic Vγ9Vδ2 T cells CULTURED CELLS Unedited cells Adoptive cellular immunotherapy using ex vivo expanded allogeneic gamma-delta (Vγ9Vδ2) T lymphocytes that recognize phosphoantigens via BTN3A1/BTN2A1 and stress ligands via NKG2D to mediate HLA-independent cytotoxicity. Ex vivo expanded allogeneic Vγ9Vδ2 T cells that recognize tumor-associated phosphoantigens via BTN3A1/BTN2A1 and stress-induced ligands via NKG2D, enabling HLA-independent cytotoxicity through perforin/granzyme release and cytokine production. MICA is an NKG2D ligand; allogeneic Vγ9Vδ2 T cells bind MICA via NKG2D and directly kill target cells through perforin/granzyme release (and death receptor pathways). Hematologic Diseases CANCER Other Lymphatic Cancer Lymphoid Neoplasm ai
MICB NCT05755854 MICB receptor ligand recognition Allogeneic Vγ9Vδ2 T cells CULTURED CELLS Unedited cells Adoptive cellular immunotherapy using ex vivo expanded allogeneic gamma-delta (Vγ9Vδ2) T lymphocytes that recognize phosphoantigens via BTN3A1/BTN2A1 and stress ligands via NKG2D to mediate HLA-independent cytotoxicity. Ex vivo expanded allogeneic Vγ9Vδ2 T cells that recognize tumor-associated phosphoantigens via BTN3A1/BTN2A1 and stress-induced ligands via NKG2D, enabling HLA-independent cytotoxicity through perforin/granzyme release and cytokine production. Vγ9Vδ2 T cells engage MICB via NKG2D, triggering degranulation and killing target cells through perforin/granzyme-mediated cytotoxicity. Hematologic Diseases CANCER Other Lymphatic Cancer Lymphoid Neoplasm ai
ULBP1 NCT05755854 ULBP1 receptor ligand recognition Allogeneic Vγ9Vδ2 T cells CULTURED CELLS Unedited cells Adoptive cellular immunotherapy using ex vivo expanded allogeneic gamma-delta (Vγ9Vδ2) T lymphocytes that recognize phosphoantigens via BTN3A1/BTN2A1 and stress ligands via NKG2D to mediate HLA-independent cytotoxicity. Ex vivo expanded allogeneic Vγ9Vδ2 T cells that recognize tumor-associated phosphoantigens via BTN3A1/BTN2A1 and stress-induced ligands via NKG2D, enabling HLA-independent cytotoxicity through perforin/granzyme release and cytokine production. Vγ9Vδ2 T cells express NKG2D, which binds ULBP1 on target cells, triggering activation and direct killing via perforin/granzyme-mediated cytotoxicity (and death receptor pathways). Hematologic Diseases CANCER Other Lymphatic Cancer Lymphoid Neoplasm ai
Displaying 871 - 875 of 3741